UGT1A1 genotype as an indicator of neutropenia for FOLFOXIRI with bevacizumab in patients with mCRC (QUATTRO study)

被引：0
|
作者：
Oki, Eiji [1 ]
Yoshino, Takayuki [2 ]
Muro, Kei [3 ]
Emi, Yasunori [4 ]
Tsuji, Akihito [5 ]
Yamasaki, Kentaro [10 ]
Yamanaka, Takeharu [7 ]
Sakisaka, Hideki [6 ]
Kato, Takeshi [8 ]
Kanazawa, Akiyoshi [9 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan
[5] Kagawa Univ, Takamatsu, Kagawa, Japan
[6] Osaka Minato Cent Hosp, Osaka, Japan
[7] Yokohama City Univ, Yokohama, Kanagawa, Japan
[8] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[9] Kitano Hosp, Osaka, Japan
[10] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY-17-2
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study)
    Takeshi, Kato
    Takayuki, Yoshino
    Kei, Muro
    Kentaro, Yamazaki
    Tatsuro, Yamaguchi
    Eiji, Oki
    Shigeyoshi, Iwamoto
    Akihito, Tsuji
    Goro, Nakayama
    Yasunori, Emi
    Tetsuo, Touyama
    Masato, Nakamura
    Masahito, Kotaka
    Hideaki, Bando
    Yoshinori, Kagawa
    Hiroya, Taniguchi
    Takeharu, Yamanaka
    Akiyoshi, Kanazawa
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Primary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study
    Bando, H.
    Kato, T.
    Yoshino, T.
    Muro, K.
    Yamazaki, K.
    Yamaguchi, T.
    Oki, E.
    Iwamoto, S.
    Tsuji, A.
    Nakayama, G.
    Emi, Y.
    Touyama, T.
    Nakamura, M.
    Kotaka, M.
    Kagawa, Y.
    Taniguchi, H.
    Sakisaka, H.
    Yamanaka, T.
    Kanazawa, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 (FFCD 0504 trial): Final results
    Mitry, E.
    Bouche, O.
    Seitz, J.
    Etienne, P.
    Legoux, J.
    Aparicio, T.
    Breysacher, G.
    Lecaille, C.
    Lecomte, T.
    Jouve, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).
    Sharma, Manish
    Toffoli, Giuseppe
    Buonadonna, Angela
    Marangon, Elena
    Polite, Blase N.
    Frustaci, Sergio
    Innocenti, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 (FFCD 0504 trial). Results of a planned interim analysis
    Mitry, E.
    Bouche, O.
    Dahan, L.
    Bonnetain, F.
    Laurent-Puig, P.
    Aparicio, T.
    Etienne, P. L.
    Lecaille, C.
    Lafargue, J. P.
    Jouve, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] UGT1A1 genotyping and neutropenia risk
    Vasconcelos, Alberto
    LANCET ONCOLOGY, 2007, 8 (10): : 873 - 873
  • [7] UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
    Hoskins, Janelle M.
    Goldberg, Richard M.
    Qu, Pingping
    Ibrahim, Joseph G.
    McLeod, Howard L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) : 1290 - 1295
  • [8] Inducibility of UGT1A1 mRNA is dependent on UGT1A1*28 genotype.
    Cascorbi, I
    Remmler, C
    Haenisch, S
    Hecker, U
    Siegmund, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P34 - P34
  • [9] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165
  • [10] Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
    Satoh, Taroh
    Ura, Takashi
    Yamada, Yasuhide
    Yamazaki, Kentaro
    Tsujinaka, Toshimasa
    Munakata, Masaki
    Nishina, Tomohiro
    Okamura, Shu
    Esaki, Taito
    Sasaki, Yasutsuna
    Koizumi, Wasaburo
    Kakeji, Yoshihiro
    Ishizuka, Naoki
    Hyodo, Ichinosuke
    Sakata, Yuh
    CANCER SCIENCE, 2011, 102 (10) : 1868 - 1873
12345